Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 1
1983 5
1984 4
1985 3
1986 9
1987 13
1988 17
1989 10
1990 13
1991 10
1992 17
1993 16
1994 18
1995 21
1996 14
1997 18
1998 16
1999 18
2000 22
2001 9
2002 16
2003 18
2004 12
2005 19
2006 15
2007 21
2008 19
2009 22
2010 30
2011 24
2012 22
2013 31
2014 22
2015 12
2016 19
2017 15
2018 12
2019 14
2020 14
2021 7
2022 7
2023 4
2024 12
2025 15
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

616 results

Results by year

Filters applied: . Clear all
Page 1
Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial.
ACCURE Study Group. ACCURE Study Group. Lancet Gastroenterol Hepatol. 2025 Jun;10(6):550-561. doi: 10.1016/S2468-1253(25)00026-3. Epub 2025 Apr 11. Lancet Gastroenterol Hepatol. 2025. PMID: 40228513 Free PMC article. Clinical Trial.
The prespecified primary outcome was the proportion of patients with a disease relapse within 1 year, predefined as a total Mayo score of 5 or higher with an endoscopic subscore of 2 or 3, or, in absence of endoscopy, based on a centrally independent masked review by a critical e …
The prespecified primary outcome was the proportion of patients with a disease relapse within 1 year, predefined as a total Mayo score of 5 …
Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis.
Cuffari C, Pierce D, Korczowski B, Fyderek K, Van Heusen H, Hossack S, Wan H, Edwards AY, Martin P. Cuffari C, et al. Drug Des Devel Ther. 2016 Feb 4;10:593-607. doi: 10.2147/DDDT.S95316. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 26893546 Free PMC article. Clinical Trial.
BACKGROUND: Limited data are available on mesalamine (5-aminosalicylic acid; 5-ASA) use in pediatric ulcerative colitis (UC). AIM: To evaluate pharmacokinetic and safety profiles of 5-ASA and metabolite acetyl-5-ASA (Ac-5-ASA) after once-daily, oral administration of multi …
BACKGROUND: Limited data are available on mesalamine (5-aminosalicylic acid; 5-ASA) use in pediatric ulcerative colitis (UC). AIM: To …
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, Kanke K, Kobayashi K, Hirai F, Watanabe K, Mizusawa H, Kishida S, Miura Y, Ohta A, Kajioka T, Hibi T; AJM300 Study Group. Matsuoka K, et al. Lancet Gastroenterol Hepatol. 2022 Jul;7(7):648-657. doi: 10.1016/S2468-1253(22)00022-X. Epub 2022 Mar 30. Lancet Gastroenterol Hepatol. 2022. PMID: 35366419 Clinical Trial.
Patients with a Mayo Clinic score of 6-10, endoscopic subscore of 2 or more, rectal bleeding subscore of 1 or more, and an inadequate response or intolerance to mesalazine were enrolled. Patients were randomly allocated (1:1) via a website to either AJM300 (960 mg) or plac …
Patients with a Mayo Clinic score of 6-10, endoscopic subscore of 2 or more, rectal bleeding subscore of 1 or more, and an inadequate respon …
Addition of pulse corticosteroids to oral prednisone in moderately active ulcerative colitis: a randomized, multicentre, open-label study by GETECCU.
Llaó J, Mañosa M, Martín-Arranz E, Zabana Y, Navarro-Llavat M, Téller M, Garcia-Planella E, Busquets D, Monfort D, Pineda JR, Gutiérrez A, Villoria A, Menchén L, Bastida G, García-Alonso FJ, Rivero M, Chaparro M, de Francisco R, Merino O, Rodríguez-Lago I, Barreiro-de Acosta M, Rodríguez-Fortúnez P, Rodríguez-Jiménez C, Calafat M, Domènech E; CECUM study group of the GETECCU. Llaó J, et al. J Crohns Colitis. 2025 Dec 5;19(11):jjaf182. doi: 10.1093/ecco-jcc/jjaf182. J Crohns Colitis. 2025. PMID: 41258993 Clinical Trial.
All patients who responded started oral mesalazine and were followed up until month 12 or clinical relapse. RESULTS: Seventy-five patients were randomized: 39 were allocated to the CT arm and 36 to the AP arm. ...
All patients who responded started oral mesalazine and were followed up until month 12 or clinical relapse. RESULTS: Seventy-five pat …
5-ASA enema therapy.
Hanauer SB. Hanauer SB. Neth J Med. 1989 Jun;35 Suppl 1:S11-20. Neth J Med. 1989. PMID: 2702307 Review.
Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
Ishikawa H, Mutoh M, Sato Y, Doyama H, Tajika M, Tanaka S, Horimatsu T, Takeuchi Y, Kashida H, Tashiro J, Ezoe Y, Nakajima T, Ikematsu H, Hori S, Suzuki S, Otani T, Takayama T, Ohda Y, Mure K, Wakabayashi K, Sakai T. Ishikawa H, et al. Lancet Gastroenterol Hepatol. 2021 Jun;6(6):474-481. doi: 10.1016/S2468-1253(21)00018-2. Epub 2021 Apr 2. Lancet Gastroenterol Hepatol. 2021. PMID: 33812492 Clinical Trial.
There were four groups: aspirin (100 mg per day) plus mesalazine (2 g per day), aspirin (100 mg per day) plus mesalazine placebo, aspirin placebo plus mesalazine (2 g per day), or aspirin placebo plus mesalazine placebo. ...FINDINGS: Between Sept 25, 2 …
There were four groups: aspirin (100 mg per day) plus mesalazine (2 g per day), aspirin (100 mg per day) plus mesalazine place …
Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation -- a placebo-controlled study.
Watanabe M, Nishino H, Sameshima Y, Ota A, Nakamura S, Hibi T. Watanabe M, et al. Aliment Pharmacol Ther. 2013 Aug;38(3):264-73. doi: 10.1111/apt.12362. Epub 2013 Jun 5. Aliment Pharmacol Ther. 2013. PMID: 23734840 Clinical Trial.

RESULTS: The endoscopic remission rates after 4 weeks in the mesalazine and placebo suppository groups were 81.5% and 29.7%, respectively, and the superiority of mesalazine to placebo was confirmed (P < 0.0001, chi-squared test). ...The superiority of mesalazi

…
RESULTS: The endoscopic remission rates after 4 weeks in the mesalazine and placebo suppository groups were 81.5% and 29.7%, respecti …
616 results